Results 1 to 10 of about 26,051 (185)

Utility and pitfalls of the electrocardiogram in the evaluation of cardiac amyloidosis

Annals of Noninvasive Electrocardiology, 2022
Background Cardiac amyloidosis is a protein misfolding disorder involving deposition of amyloid fibril proteins in the heart. The associated fibrosis of the conduction tissue results in conduction abnormalities and arrhythmias.
Perryn Lin Fei Ng, Yoke Ching Lim, Lauren Kay Mance Evangelista, Raymond Ching Chiew Wong, Ping Chai, Ching Hui Sia, Hoi Yin Loi, Tiong Cheng Yeo, Weiqin Lin   +8 more
doaj   +1 more source

Blood-based microRNA profiling in patients with cardiac amyloidosis. [PDF]

PLoS ONE, 2018
INTRODUCTION:Amyloidosis is caused by dysregulation of protein folding resulting in systemic or organ specific amyloid aggregation. When affecting the heart, amyloidosis can cause severe heart failure, which is associated with a high morbidity and ...
Anselm A Derda, Angelika Pfanne, Christian Bär, Katharina Schimmel, Peter J Kennel, Ke Xiao, P Christian Schulze, Johann Bauersachs, Thomas Thum   +8 more
doaj   +1 more source

Survival Following Implantable Cardioverter‐Defibrillator Implantation in Patients With Amyloid Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020
Background Outcomes data in patients with cardiac amyloidosis after implantable cardioverter‐defibrillator (ICD) implantation are limited. We compared outcomes of patients with ICDs implanted for cardiac amyloidosis versus nonischemic cardiomyopathies ...
Angela Y. Higgins, Amarnath R. Annapureddy, Yongfei Wang, Karl E. Minges, Rachel Lampert, Lynda E. Rosenfeld, Daniel L. Jacoby, Jeptha P. Curtis, Edward J. Miller, James V. Freeman   +9 more
doaj   +1 more source

Transthyretin cardiac amyloidosis in patients after TAVR: clinical and echocardiographic findings and long term survival

ESC Heart Failure, 2021
Aims The aim of this study was to examine the prevalence of amyloid transthyretin (ATTR) cardiac amyloidosis in patients 1–2 years after trans‐catheter aortic valve replacement (TAVR) and to assess their clinical and echocardiographic outcome and long ...
Sara Shimoni, Meital Zikri, Dan Haberman, Shay Livschitz, Sagi Tshori, Yacov Fabricant, Valery Meledin, Gera Gandelman, Sorel Goland, Jacob George   +9 more
doaj   +1 more source

Clinical Clues and Diagnostic Workup of Cardiac Amyloidosis

Methodist DeBakey Cardiovascular Journal, 2022
Cardiac amyloidosis is increasingly recognized as an underlying cause of left ventricular wall thickening, heart failure, and arrhythmia with variable clinical presentation.
Sajan S. Gill, Eric Fellin, Lisa Stampke, Yuanzi Zhao, Ahmad Masri   +4 more
doaj   +1 more source

Technetium-99m pyrophosphate cardiac SPECT in endomyocardial biopsy negative cardiac amyloidosis

Radiology Case Reports, 2018
Cardiac amyloidosis is an under-appreciated cause of heart failure. Establishing a diagnosis is important because traditional heart failure treatment regimens can worsen left ventricular failure in this disease. Endomyocardial biopsy is the gold standard
Martin Krupa, MD, Rina Nguyen, BS, Jonathan Revels, DO, Lester S. Johnson, MD, PhD, FACR   +3 more
doaj   +1 more source

Plasma Hepatocyte Growth Factor for Diagnosis and Prognosis in Light Chain and Transthyretin Cardiac Amyloidosis

JACC. CardioOncology, 2020
Objectives: This study determined the diagnostic and prognostic usefulness of hepatocyte growth factor (HGF) in light chain and transthyretin cardiac amyloidosis.
Kathleen W. Zhang, MD, Jennifer Miao, MD, Joshua D. Mitchell, MD, Jose Alvarez-Cardona, MD, Kelsey Tomasek, BS, Yan Ru Su, MD, Mary Gordon, RN, R. Frank Cornell, MD, Daniel J. Lenihan, MD   +8 more
doaj   +1 more source

Potential clinical relevance of cardiac magnetic resonance to diagnose cardiac light chain amyloidosis.

PLoS ONE, 2022
BackgroundWhile patients with cardiac transthyretin amyloidosis are easily diagnosed with bone scintigraphy, the detection of cardiac light chain (AL) amyloidosis is challenging.
Zsofia Dohy, Liliana Szabo, Zoltan Pozsonyi, Ibolya Csecs, Attila Toth, Ferenc Imre Suhai, Csilla Czimbalmos, Andrea Szucs, Anna Reka Kiss, David Becker, Bela Merkely, Hajnalka Vago   +11 more
doaj   +1 more source

Rapid decline in ejection fraction and persistent elevation of troponin associated with cardiac amyloidosis

SAGE Open Medical Case Reports, 2020
Cardiac amyloidosis is an increasingly recognized cause of heart failure. It remains underdiagnosed despite a significant morbidity and mortality rate. The mean survival in patients with cardiac amyloidosis is less than 1 year in untreated primary light ...
Temidayo Abe, Eric Y Chang, Gabrielle De Allie, Taiwo Ajose, Chukwuemeka Nwokike, Nicolas Bakinde   +5 more
doaj   +1 more source

Cardiac Transthyretin Amyloidosis: Hidden in Plain Sight

Case Reports in Medicine, 2021
Amyloidosis is an underappreciated medical condition with symptoms camouflaging as common medical comorbidities leading to its underdiagnosis due to its systemic involvement.
Constantine N. Logothetis, Joel Fernandez, Damian A. Laber   +2 more
doaj   +1 more source